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Modern-day healthcare is becoming increasingly information intensive including at the 
personal level. The genomic data made available by the Human Genome Project gave this trend 
a great deal of impetus as did the more recent emergence of big data analytics alongside 
unprecedented computing power including artificial intelligence, enabling the generation of 
useful health-relevant information out of vast genomic and other datasets. Digitally recorded 
and annotated genetic and other molecular information acquired from large numbers of people, 
especially when combined with other information (lifestyle, family, personal electronic health 
history records etc.) coming from a wide range of sources, can provide not only a massive 
volume of health related data for analysis, but also diversity in kinds of information we can 
derive, from responsiveness to drugs, to likelihood of contracting particular diseases, and ways 
to prevent or reduce risk of certain diseases later in life. It is not just healthcare in the broad 
sense that is moving onto computer screens; medicine is becoming digital as much as it is 
chemical, especially when treatment concerns itself more and more with disease prediction, 
diagnosis, prognosis, and monitoring of sickness, health and treatment effects and side-effects, 
and of course with personalisation. According to one recent article on the subject, “the patient 
is an enormous repository of information that needs to be harvested as a partnership not only 
in clinical care but in discovery… The ability to stratify the phenotypic expression of wellness 
and disease will ultimately lead to better validation of human therapeutic targets for drug 
discovery” (D Ausiello, quoted in Elenco et al 2015). 
 
Personalised medicine is one aspect, perhaps the most important, of the efforts currently being 
made by biomedical scientists and industry to enhance targeting of disease to achieve better 
health outcomes for more people. Personalised medicine deals with the tailoring of treatments 
in a way that responds to the variability of human beings, and to the fact that single diseases 
may really be families of sub-diseases. It implies individualisation of medical attention but 
whereas it does involve the testing of people for certain biomarkers conveying diagnostic or 
therapy-related information, those biomarkers are typically ones shared with other people. It is 
not a passing trend, but is reshaping the field of medicine.  
 
Ideally, science policies would translate scientific research into technological innovation that 
benefits society. However, available medicines in many therapeutic areas are actually not very 
good even if they are very effective for some people. According to a recent study not one of 
the ten bestselling drugs in the United States helps the majority of patients who are given them. 
In fact, they benefit only ‘between 1 in 25 and 1 in 4 of the people who take them. For some 
drugs, such as statins – routinely used to lower cholesterol – as few as 1 in 50 may benefit’ 
(Schork 2015). In a 2001 article on pharmacogenetics, the authors found efficacy rates of major 
medicines in several areas to be very low: a 25 percent efficacy rate in oncology, 30 percent in 
Alzheimer’s, 47 percent for hepatitis C virus, and 48 percent in osteoporosis to give a few 
examples (Spear, Heath-Chiozzi and Huff 2001). In addition, adverse drug reactions can cause 
deaths. Doubtless, some of these figures have improved in the years since then. For example, 
there are now medicines that can cure hepatitis C virus.  
 
Thus, pharmaceutical companies’ record of delivering truly innovative products in recent years 
is disappointing. In an influential article published in Nature Reviews Drug Discovery 
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(Scannell, Blanckley, Boldon and Warrington 2012),1 the authors find that the decline actually 
began around 1950, whether or not it was perceived at the time. The authors posit that from 
that year onwards the number of medicines approved per billion dollars spent on research and 
development has on average halved every nine or so years. The fall is quite modest during the 
1950s but then steepens from 1960. They call this phenomenon Eroom’s Law (which is the 
famous and much more optimistic Moore’s Law written backwards). 
 
There is unlikely to be a single reason for this. However, the traditional innovation model based 
on the idea of strong intellectual property (IP) rights whose main function is to exclude 
competitors is seen by many critics as one factor. Given that data-driven medicine requires the 
mining of data of various types and from a wide range of sources, both public and private, 
weakness in the current IP-based innovation models seem likely if anything to become more 
serious. Why? Because IP rights inhibits sharing and collaboration at a time when these have 
never been more essential.  Moreover, universities, patients and users participate in data driven 
innovation, which makes the picture more complicated. Moreover, exclusion and control sit 
uncomfortably with patients’ and users’ altruistic motives and universities’ public mission. 
Unsurprisingly, the boundary between the open and the proprietary is passionately debated and 
constantly in flux: more open here, increasingly proprietary there, but with a tendency to be 
more of the latter and less of the former.  
 
Openness in innovation is many times suggested as the solution. To some extent it is already 
being applied. As the Human Genome Project was coming to an end it became clearer than 
ever that much would be gained both scientifically and therapeutically from studying the 
genetic variability within the human species. One key unit of such variability was at the tiny 
level of the individual nucleotide base. Such variations shared by reasonably large numbers of 
people, and forming 90 percent of the genetic variability of our species, are called single 
nucleotide polymorphisms (SNPs). In 1999, a group of companies and research organisations 
together with the Wellcome Trust, then the world’s largest medical charity, established the 
SNP Consortium. Its aim was to identify all of the common SNPs, of which there are now 
believed to be around 10 million, and map them onto the human genome. From the private 
sector, Glaxo Wellcome (as it was then called) took the initiative in starting such an endeavour 
but after meeting the Wellcome Trust and some other companies during 1998, it was decided 
that the ideal approach would be to establish a consortium. Funding came from the Trust and 
several large pharmaceutical company members and IBM and Motorola. In 2001 their shared 
data on SNPs was publicly released.  
 
A similar pooling of public data was undertaken by the International HapMap Consortium, 
which comprised an international group of funders, government agencies and universities from 
the United States, the UK, Canada, China, Japan, Nigeria, as well as the SNP Consortium plus 
two biotech firms, Illumina and ParAllele Bioscience (The International HapMap Consortium, 
2003). It has turned out that many SNPs throughout the genome are inherited together as 
‘blocks’. A haplotype is the arrangement of SNPs on each of these blocks. Given that the 
number of haplotypes is far lower than the quantity of SNPs, generating such a map offered an 
extremely convenient short cut in studying human genetic variability. The HapMap Project, 
the first phase of which was completed in 2005 (Goldstein and GL Cavalleri 2005), and the 
final one in 2009, required users to agree to a license that undertook them not to reduce access 
to the data or to pass data on to non-licensees.2  
                                                            
1 The rest of this subsection draws on this article. 




Such collaborative approaches and licensing schemes are not a rejection of intellectual property 
rights per se. Indeed, intellectual property protection may be necessary for ‘open source’ 
collaborative models to work. They do emphasize and seek to encourage collaboration of the 
kind that aggressive assertion of patent and other intellectual property claims would certainly 
preclude. The use of intellectual property rights is the best available sanction against those who 
acquire data and then seek legal protection covering elements of the received data and who 
may not be bound by any license. But of course the hope is that litigation is the last resort. This 
has been the case in software development, where open source collaborative models and 
licensing were first tried out with great success.3 In fact, while the SNP Consortium’s 
intellectual property procedures were for patent applications to be filed for any inventions 
arising, the point of doing so was not to claim monopoly protection but to record their priority 
dates so as to block patenting by others (Holden 2002). Currently the Structural Genomics 
Consortium, a charitable international partnership of non-profit foundations corporations has a 
policy of sharing freely and filing no patents on its discoveries. 
 
Openness sound like a straightforward concept. However, its meaning remains elusive. On the 
one extreme we see such terms as “Open Data,” “Open Software” and “Open Access”. These 
present openness as a way to enhance transparency and collaboration (Benkler 2016), and 
preserve integrity and creativity.4 On the other extreme, we see proprietary regimes, with 
“closed” data and legal rights such as patents being fundamental (the dominant pharmaceutical 
innovation model). However, commentators increasingly recognise that, for one thing, there 
are shades of openness. “Open innovation”, a concept coined by Henry Chesbrough (2003), 
has been embraced by many in the pharmaceutical industry but while it does indeed involve 
sharing of knowledge, expertise and materials, it hardly deviates from the industry’s patent-
dependent business models. Even open source depends on copyright rules (Dusollier 2007). 
For another, the “closed” and “open” dynamically interweave (Hilgartner 2012). The latter 
relationship is the focus of the contributions of the special issue. Openness in this framework 
is not only a technical problem to be solved but also has a social, cultural, and moral facet.5  
 
The question remains: how well do we strike the right balance in terms of promoting socially-
optimal innovation? And how would one determine the ideal place to strike such a balance 
along the spectrum between closed innovation at one end and fully open at the other end? We 
hope this special issue will at the very least contribute to enhanced understanding of how these 
questions might best be resolved. Let us now turn to the contributions. 
 
Regulatory rules and court decisions are one place where the balance between the open and 
closed is negotiated, but as we will see they are not the only ‘spaces’ where this happens. 
Recent decisions by the US Supreme Court placed genes and diagnostic methods outside the 
realm of patent protection proclaiming them non-eligible subject matter that cannot be the 
subject of private property. In Europe the balance continues to be struck in favour of more 
expanded eligibility in this area. On the other hand, the latter jurisdiction continues to have 
                                                            
3 For an excellent and highly detailed discussion on the applicability of open source to biotechnology including 
reviews of several ongoing open source biotechnology initiatives, see Hope (2008). 
4 European Commission, (2014) “Consultation on ‘Science 2.0’: Science in Transition,” Accessed November 
21, 2017 http://ec.europa.eu/research/consultations/science-2.0/consultation_en.htm. 
5 Nuffield Council on Bioethics (2015) “The Collection, Linking and Use of Data in Biomedical Research and 
Health Care: Ethical Issues.” Accessed November 25, 2017 http://nuffieldbioethics.org/wp-
content/uploads/Biological_and_health_data_web.pdf; Michael A. Peters. “Open Science, Philosophy and Peer 
Review.” Educational Philosophy and Theory (2014) 46 (3): 215–19. 
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broader exclusions in other areas of biomedicine as well as a ban on the patentability of 
inventions whose commercial use would be immoral and contrary to ordre public. However, 
as our contributors discuss, extending legal rights to one type of scientific research product that 
we preclude from others affects how societies innovate. Shubha Ghosh explains that denying 
patents may influence the shift of commercial activity from genes to genetic data mining. In 
this sense, court decisions influence politics and the future development of industry in indirect 
ways. Katerina Sideri argues that these decisions reflect policy choices and a particular 
understanding of the proper role of the state in regulating the marketplace and knowledge 
production in the emerging information economy. In their respective contributions, both 
authors claim that these decisions essentially endorse practices of data processing which 
constitute a new type of public domain necessary for fueling the development of the new data-
mining and analytics tools and the next generation of data intensive therapeutics in the field of 
data driven medicine. These technologies learn from data to predict the future behavior of 
individuals in order to drive better decisions. 
 
Outside of the courts, and perhaps more significantly, the relationship between ‘open’ and 
‘closed’ in innovation depends on social norms and values (Botsrom, 2017). In this sense, 
openness often invites the notion of participation, which is infused with the ideas of social 
solidarity and altruism, a far cry from the idea of impersonal exchanges in vast global markets 
that property rights imply. Thus, the social meaning of openness is negotiated in the context of 
clinical applications of revolutionary technologies such as cell-free foetal DNA prenatal 
testing, which simplifies testing for abnormalities in the foetus. Naomi Hawkins discusses the 
rapid development and widespread adoption of the technology in the clinic around the world, 
and employs qualitative analysis of interview material with users of technologies to question 
the extent to which and the reasons for failure to comply with patent law. This approach 
resonates well with Shobita Parthasarathy’s contribution advocating the expansion of 
qualitative research on patents and intellectual property related to innovation. There is urgent 
need for policy makers to go beyond economic analysis so as to come to grips with the broader 
implications of intellectual property for social and political orders. In fact, Shobita 
Parthasarathy argues that this qualitative research can help governments produce patent 
decisions and policies that are both more socially beneficial and politically legitimate. 
 
To turn to other legal and policy developments in Europe that go beyond patents, Timo 
Minssen, Rajam Neethu and Marcel Bogers discuss openness in the context of initiatives with 
respect to transparency of clinical trial data and note the potential tensions with the General 
Data Protection Regulation (GDPR) in the EU.  For the GDPR the question of openness is 
viewed through the angle of user control of data in the era of big data analytics, but the policy 
goals behind transparency of clinical trial data seem to be quite different: the focus is on 
promoting science and open innovation that will benefit society at large and is based on the 
understanding that data sharing and open innovation go hand-in-glove. Highligting the tensions 
between these two levels of openness is imporatnt and links to the more theoretical discussion 
of Barbara Prainsack’s paper, the last contributor of the special issue. Barbara Prainsack 
elegantly summarizes the theoretical nuances of the notion of openness in the context of 
Personalised and Precision Medicine. Her argument is that different theorizations pose 
different goals for public policy. She identifies three ways to theorize openness: the 
‘ontological,’ the ‘pluralistic’ and the ‘emancipatory’. The ‘ontological sense’ relates to 
openness at the level of the person,  the ‘pluralistic sense’ brings to the foreground the plurality 
of perspectives and values, while  the ‘emancipatory sense,’ poses questions with regard to  
concentrations of power of corporate actors dominating the field  of innovation in data driven 
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medicine. Depending on the choice of theoretical approach the focus of key goals for public 
policy shifts.  
 
In short, the special issue seeks to discuss the notion of openness in data driven medicine and 
contributors are social scientists who contribute to this debate by looking into the questions 
economists cannot answer. All contributors write in the fields of law, political science and 
Science and Technology Studies.  
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